Literature DB >> 36176647

Learning Methodological Lessons from Exemplar Studies in Nephrology: PEXIVAS and Sample Size Calculation.

Vicki Sandys1, Donal J Sexton2,3.   

Abstract

Sample size calculations are fundamental to the power of a study. Estimates of the necessary sample size to achieve a given treatment effect size can be performed pre-trial based on available literature.Sample size calculations take into account the chosen effect size i.e. the minimal effect of the treatment which would be considered clinically relevant. Smaller effect sizes require a sufficiently large sample size or higher event rate to detect differences between groups. Larger effect sizes are sometimes chosen for study in order to justify the risks of adverse events and expense of certain treatments.Lower than expected event rates, mediated by censoring and competing risks, period effects, and inclusion of patients at lower risk of the outcome, can impact the power of the study.Time-to-event study designs adjust for censoring and competing risks.If a lower than expected event rate is highlighted during an interim analysis, strategies include increasing the sample size, either by changing the inclusion or exclusion criteria, increasing the number of study centers or increasing the study duration.
Copyright © 2022 by the American Society of Nephrology.

Entities:  

Keywords:  PEXIVAS; clinical nephrology; plasma exchange; plasmapheresis; sample size

Mesh:

Year:  2022        PMID: 36176647      PMCID: PMC9416842          DOI: 10.34067/KID.0005052021

Source DB:  PubMed          Journal:  Kidney360        ISSN: 2641-7650


  5 in total

1.  Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. Reply.

Authors:  Michael Walsh; Peter A Merkel; David R W Jayne
Journal:  N Engl J Med       Date:  2020-05-28       Impact factor: 91.245

2.  Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.

Authors:  Michael Walsh; Peter A Merkel; Chen-Au Peh; Wladimir M Szpirt; Xavier Puéchal; Shouichi Fujimoto; Carmel M Hawley; Nader Khalidi; Oliver Floßmann; Ron Wald; Louis P Girard; Adeera Levin; Gina Gregorini; Lorraine Harper; William F Clark; Christian Pagnoux; Ulrich Specks; Lucy Smyth; Vladimir Tesar; Toshiko Ito-Ihara; Janak Rashme de Zoysa; Wojciech Szczeklik; Luis Felipe Flores-Suárez; Simon Carette; Loïc Guillevin; Charles D Pusey; Alina L Casian; Biljana Brezina; Andrea Mazzetti; Carol A McAlear; Elizabeth Broadhurst; Donna Reidlinger; Samir Mehta; Natalie Ives; David R W Jayne
Journal:  N Engl J Med       Date:  2020-02-13       Impact factor: 91.245

3.  Kidney Histopathology Can Predict Kidney Function in ANCA-Associated Vasculitides with Acute Kidney Injury Treated with Plasma Exchanges.

Authors:  Dorian Nezam; Raphaël Porcher; François Grolleau; Pauline Morel; Dimitri Titeca-Beauport; Stanislas Faguer; Alexandre Karras; Justine Solignac; Noémie Jourde-Chiche; François Maurier; Hamza Sakhi; Khalil El Karoui; Rafik Mesbah; Pierre Louis Carron; Vincent Audard; Didier Ducloux; Romain Paule; Jean-François Augusto; Julien Aniort; Aurélien Tiple; Cédric Rafat; Séverine Beaudreuil; Xavier Puéchal; Pierre Gobert; Ziad Massy; Catherine Hanrotel; Stéphane Bally; Nihal Martis; Cécile-Audrey Durel; Geoffroy Desbuissons; Pascal Godmer; Aurélie Hummel; François Perrin; Antoine Néel; Claire De Moreuil; Tiphaine Goulenok; Dominique Guerrot; Steven Grange; Aurélie Foucher; Alban Deroux; Carole Cordonnier; Céline Guilbeau-Frugier; Anne Modesto-Segonds; Dominique Nochy; Laurent Daniel; Anissa Moktefi; Marion Rabant; Loïc Guillevin; Alexis Régent; Benjamin Terrier
Journal:  J Am Soc Nephrol       Date:  2022-01-24       Impact factor: 10.121

4.  Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis.

Authors:  David R W Jayne; Gill Gaskin; Niels Rasmussen; Daniel Abramowicz; Franco Ferrario; Loic Guillevin; Eduardo Mirapeix; Caroline O S Savage; Renato A Sinico; Coen A Stegeman; Kerstin W Westman; Fokko J van der Woude; Robert A F de Lind van Wijngaarden; Charles D Pusey
Journal:  J Am Soc Nephrol       Date:  2007-06-20       Impact factor: 10.121

5.  Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial.

Authors:  Michael Walsh; Peter A Merkel; Chen Au Peh; Wladimir Szpirt; Loïc Guillevin; Charles D Pusey; Janak De Zoysa; Natalie Ives; William F Clark; Karen Quillen; Jeffrey L Winters; Keith Wheatley; David Jayne
Journal:  Trials       Date:  2013-03-14       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.